safeguard scientifics inc (SFE:New York)

Executive Profile*

Background*

Mr. James A. Datin, Jim, MBA has been a Managing Director of Life Sciences and Executive Vice President at Safeguard Scientifics, Inc. since September 7, 2005. At Safeguard Scientifics, Inc, Mr. Datin leverages his expertise to drive partnership opportunities for both healthcare and technology partner companies, specifically MedTech including diagnostics and devices; HealthTech including Healthcare IT specialty pharmaceuticals; Digital Media; FinTech; and Enterprise ... 3.0, which includes mobile technology, cloud, the Internet of Things and big data. Mr. Datin served as an Executive Vice President and Managing Director of Life Sciences at NuPathe, Inc. His significant experience as a Marketing and Sales and Business Development Executive for leading pharmaceutical, medical device, diagnostics and software companies spans more than 20 years and covers assignments throughout the United States, Europe and Asia. He served as Chief Executive Officer of Publicis Touchpoint Solutions, Inc. and Golden Land Bhd. He served as Group President of Cegedim, Inc. He actively oversees Safeguard’s life sciences partner companies and continuously evaluate new growth opportunities for both the healthcare and technology groups. Mr. Datin was employed at Quinnova Pharmaceuticals, Inc. since September 7, 2005. He served as the Chief Executive Officer of Touchpoint Solutions, Inc., from 2004 to 2005. He served as the Group President in 2004 and Group President of International of Dendrite International from 2001 to 2003. He served as the Group Director of Corporate Business Strategy and Planning at GlaxoSmithKline plc from 1999 to 2001. He served on the Global Predictive Medicine Board of Directors, evaluating acquisition and alliance opportunities, reengineering projects and facilitating change management teams. Prior to Glaxo Wellcome, Mr. Datin served as the Chief Executive Officer of Isuta Holdings and redesigned its value proposition and led a profitable expansion throughout Asia and enabled Isuta’s survival of the Asian economic crisis. He served as Director of International Business at Baxter International Inc. and Baxter/Merck KGaA. He has been the Chairman of Clarient Inc. since July 18, 2006 and its Director since October 18, 2005. Mr. Datin has been a Director of University City Science Center since June 2010, Molecular Biometrics Inc. since November 10, 2008 and Quinnova Pharmaceuticals Inc. since October 2009. Mr. Datin has been a Director of NuPathe, Inc. since October 23, 2012. He serves as Director of Cellumen Inc., Putney Inc., Ventaira Pharmaceuticals Inc., NovaSom Inc., Laureate Pharma Inc. and Rubicor Medical, Inc. He serves as an Executive Board Member of Celerant Consulting and Board Member of Hepatitis B Foundation. He serves as an Advisory Board Member of Sanofi Aventis. He is a Director of Sotera Wireless, Inc. Mr. Datin served as a Director of IntraLinks Holdings, Inc. since January 2004. He served as a Member of Predictive Medicine Board of Directors at GlaxoSmithKline. Mr. Datin holds an M.B.A. from University of New Haven and a B.B.A. in Marketing from Marshall University. He attended Advanced Management Program – The Wharton School at The University of Pennsylvania

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
SFE:US	$16.50 USD	+0.14

COMPETITOR COMPENSATION